On September 14, 2026, Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate the targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda (pembrolizumab) for FAP-α positive solid tumors. Under the terms of the agreement, Merck will provide pembrolizumab at no cost as part of an amendment to Perspective's ongoing Phase 1/2a study (NCT06710756), which has completed enrollment in its first three monotherapy dose cohorts. This strategic partnership aims to assess whether combining targeted radiopharmaceutical treatment with an immune checkpoint inhibitor can improve outcomes for patients with advanced solid tumors expressing fibroblast activation protein alpha. Perspective Therapeutics is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body.

Perspective Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $26.8 million, or $0.22 per share, compared to a net loss of $21.5 million in the prior year period. Research and development expenses increased to $21.5 million from $16.6 million, while general and administrative expenses remained stable at $7.8 million. The company held approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which management believes is sufficient to fund operations into late 2027. Clinically, the company advanced its VMT-α-NET program toward a Phase 3 study in neuroendocrine tumors, with site activation targeted for year-end 2026 subject to regulatory feedback. Perspective Therapeutics operates as a radiopharmaceutical development company pioneering alpha-emitting treatments for cancers.